Tempest Therapeutics News

Tempest Therapeutics Reported Amezalpat (TPST-1120) Arm Improves All Efficacy Endpoints Vs. SoC Control In Study Of Amezalpat (TPST 1120) In First Line Hepatocellular Carcinoma

Tempest Therapeutics Reported Amezalpat (TPST-1120) Arm Improves All Efficacy Endpoints Vs. SoC Control In Study Of Amezalpat (TPST 1120) In First Line Hepatocellular Carcinoma

Benzinga49minutes ago

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersNexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. The company's market cap stands at $11.4 million. Tempest Therapeutics (NASDAQ:TPST) s

Benzinga16:30 ET

Tempest to Report New Data From Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

PDF Version Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ETBRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage b

Tempest TherapeuticsJun 18 00:00 ET

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP ("GPM") announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors' and officers' possible

BusinesswireMay 31 15:45 ET

Tempest to Participate in Upcoming Investor Conferences

PDF Version BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-m

Tempest TherapeuticsMay 21 00:00 ET

Express News | HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target

BenzingaMay 10 14:58 ET

Tempest Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 1368.75% HC Wainwright & Co. → $47 Reiterates Buy → Buy 03/20/2024 1368.75% HC Wainwright & Co.

BenzingaMay 10 14:57 ET

Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)

TipRanksMay 10 08:12 ET

Buy Rating Affirmed for Tempest Therapeutics Amidst Promising Clinical Advancements

TipRanksMay 10 06:25 ET

Tempest Therapeutics | 10-Q: Quarterly report

SEC announcementMay 9 16:35 ET · Announcements

Tempest Therapeutics 1Q Loss/Shr 36c >TPST

Tempest Therapeutics 1Q Loss/Shr 36c >TPST

Dow JonesMay 9 16:35 ET

Express News | Tempest Therapeutics Inc: Expects to Have Sufficient Resources to Fund Operations Into Q2 of 2025

ReutersMay 9 16:29 ET

Express News | Tempest Therapeutics Q1 EPS USD -0.36 Vs. Ibes Estimate USD -0.37

ReutersMay 9 16:29 ET

Express News | Tempest Therapeutics Q1 Net Income USD -7.904 Million Vs. Ibes Estimate USD -7.62 Million

ReutersMay 9 16:29 ET

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

PDF Version Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual M

Tempest TherapeuticsMay 9 00:00 ET

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PDF Version BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune

Tempest TherapeuticsApr 26 00:00 ET

Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments

TipRanksApr 9 11:25 ET

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

PDF Version BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune

Tempest TherapeuticsApr 9 00:00 ET

Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno

BenzingaApr 5 13:06 ET

Tempest Announces Publication of Positive Data From Phase 1 Trial of TPST-1120 in Patients With Advanced Solid Tumors in Journal of Cancer Research Communications

PDF Version TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive r

Tempest TherapeuticsApr 4 00:00 ET